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ABSTRACT
Sex steroids play a key role in bone turnover and preserving BMD; hence, gender‐affirming hormone treatment (HT) in
transgender people affects bone metabolism. Most studies have looked into the effect of HT on changes in BMD; however, they
do not provide insights into changes in bone metabolism caused by HT. This study investigated changes in bone turnover markers
(BTMs) and sclerostin, as well as their correlations with change in BMD in transwomen and transmen during the first year of HT.
Transwomen received estradiol and antiandrogens; transmen received testosterone. Sclerostin; P1NP; alkaline phosphatase (ALP);
CTx; and BMD of the total hip, the femoral neck, and the lumbar spine were evaluated at baseline and after 1 year of HT. There
were 121 transwomen (median age 30 years, interquartile range [IQR] 24 to 41 years) and 132 transmen (median age 24 years, IQR
21 to 33 years) included in the study. In transwomen, ALP decreased in 19% (95% CI, –21 to–16), CTx in 11% (95% CI, –18 to–4),
and sclerostin in 8% (95%CI, –13 to–4) of study participants after 1 year of HT. In contrast, in transmen P1NP, ALP, and sclerostin
increased in 33% (95% CI, 24 to 42), 16% (95% CI, 12 to 20), and 15% (95% CI, 10 to 20) of study participants, respectively, after
1 year of HT. No age differences were seen in transwomen, whereas in transmen aged ≥50 years a decrease in all BTMs was found
in contrast with the other age groups. These transmen had low estrogen concentration at the start of HT based on their
postmenopausal state before the start of HT; their estradiol concentrations increased during testosterone treatment. Changes in
BTMs and BMD were weakly correlated (correlation coefficient all <0.30). To conclude, 1 year of HT resulted in decreased bone
turnover in transwomen and older transmen, whereas it increased in younger transmen. The decrease in bone resorption in older
transmen shows the importance of estrogen as a key regulator of bone turnover. © 2019 The Authors. Journal of Bone and Mineral
Research published by Wiley Periodicals, Inc.
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Introduction
Sex steroids are considered to be pivotal regulators of bonemetabolism. Estrogen inhibits the osteoclast function and
thereby lowers bone resorption, resulting in a positive effect on
BMD in both women and men.(1–5) Furthermore, it is well‐
known that BMD decreases in postmenopausal women based
on decreasing estrogen concentrations and consequently
increased bone resorption by osteoclasts.(6,7) In men, estrogen
is aromatized from testosterone and is also considered to be
the key sex steroid affecting bone homeostasis.(8–10) Research
has shown that bone metabolism and therefore BMD are
affected by gender‐affirming hormone treatment (HT) in
people diagnosed with gender dysphoria(5,11–18): HT is used
to bring about desired body changes in transgender people. HT
in transmen (female‐to‐male transgender people) consists of
testosterone treatment; transwomen (male‐to‐female trans-
gender people) receive a combination of antiandrogens and
estrogens.
An increase in BMD after 1 to 10 years of treatment with HT
in transgender people has been described.(5,19) BMD is usually
evaluated by a DXA scan; however, these scans estimate the
amount of mineralized bone only and therefore represent late
changes in bone metabolism. In contrast, bone turnover
markers (BTMs) represent the actual activity of the osteoblasts
and osteoclasts. Consequently, measurements of BTMs display
the balance between bone formation and bone resorption
directly. Up until now, scarce data have been available
regarding the effect of HT on bone turnover specifically in
transgender people,(20–24) whereas no data on sclerostin are
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available yet. Clinically, increased bone turnover and lower
BMD are risk factors for the deterioration of bone quality,
resulting in possible osteopenia, osteoporosis, and even an
increased risk of fractures with its associated comorbidities and
financial costs. As the transgender population receiving HT
increases worldwide,(25,26) more transgender people are thus at
risk for lower bone quality and its associated problems.
Therefore, the aim of this study was to investigate the change
in BTMs and to evaluate the correlations with changes in BMD
in adult transgender people during their first year of HT. We
also studied possible age‐related effects on BTMs and BMD
during HT by studying transgender people in various age
groups. We hypothesized that we would find a decrease in
bone turnover predominantly caused by estrogen, as this sex
steroid is known to inhibit osteoclast function and therefore
exerts an anabolic effect on bone.
This study also focused on the bone formation markers P1NP
and total alkaline phosphatase (ALP) and the bone resorption
marker CTx. In addition, we studied the glycoprotein sclerostin,
which is known(1): to mediate an antianabolic effect on bone by
promoting the apoptosis of osteoblasts(2); to stimulate RANKL
production by osteocytes, resulting in increased osteoclasto-
genesis; and (3) to inhibit the activation of the Wnt/β‐catenin
pathway— all resulting in negative effects on BMD.(27–32)
Sclerostin is mainly produced by osteocytes and can be used as
a marker of bone metabolism as well.
Methods
Subjects and study protocol
This study is part of the European Network for Investigation of
Gender Incongruence (ENIGI) study, which is a prospective
multicenter observational study in Ghent (Belgium), Oslo
(Norway), Florence (Italy), and Amsterdam (The Netherlands).(33,34)
The current study protocol was approved by the Ethical
Committee of the Amsterdam University Medical Center, Vrije
Universiteit Amsterdam (Amsterdam, The Netherlands). Data were
retrieved only after informed consent. Adults diagnosed with
gender dysphoria based on the diagnostic criteria of the
Diagnostic and Statistical Manual of Mental Disorders, 4th edition
(DSM IV)(35) or 5th edition (DSM5)(36) were recruited at the Center
of Expertise on Gender Dysphoria of the Amsterdam University
Medical Center, between June 2012 and April 2016. All
transgender people included in this study were treated according
to the Standards of Care Guidelines of the World Professional
Association for Transgender Health (WPATH).(37) Transwomen
were treated with antiandrogen treatment consisting of cypro-
terone acetate (50 to 100mg daily, oral) accompanied by estrogen
treatment consisting of either estradiol valerate (2 to 4mg daily,
oral) or estradiol patches (50 to 100 µg/24 hours twice a week,
transdermal application). Transmen were treated with either
testosterone gel (50mg daily, dermal application), testosterone
esters (250mg every 2 to 3 weeks, i.m.), or testosterone
undecanoate (1000mg every 12 weeks, i.m.). Some transmen
used lynestrenol for a short period if menses persisted while using
testosterone.
People were not eligible to participate in the study if they
had(1): insufficient knowledge of their native language(2); were
psychologically vulnerable(3); used HT earlier in life; or (4) used
other drug therapies that were not part of the standardized
treatment protocol (eg, spironolactone or gonadotropin‐
releasing hormone agonists). For the current analyses, people
were excluded if they did not complete 1 year of HT, had no
DXA scan at baseline and/or after 1 year of HT, or had no blood
drawn at baseline and after 1 year of HT. In addition, only
people from the Amsterdam University Medical Center were
included to exclude possible changes in BTM concentrations




Participants visited the outpatient clinic every 3 months to
evaluate their health and treatment effects. Body weight
(kilograms) and height (centimeters) were measured without
wearing shoes at baseline and follow‐up. Blood samples were
collected between 9:00 a.m. and 12:00 p.m. at baseline, after
3 months, and after 1 year of HT. Participants were instructed to
draw blood in a fasting state.
Bone turnover markers
P1NP
The bone formation marker P1NP resembles osteoblast
activity(38) and was measured using an immunoassay (Cobas;
Roche Diagnostics, Mannheim, Germany), with an interassay
coefficient of variation (CV) of<8% and a lower limit of
quantification (LOQ) of 5 µg/L.
Alkaline phosphatase
The bone formation marker ALP, also representing osteoblast
activity,(38) was measured using an immunoassay (Cobas; Roche
Diagnostics), with an interassay CV of 2.5% and a LOQ of 5 U/L.
CTx
The bone resorption marker CTx displays osteoclast activity.(38)
CTx was measured using an immunoassay (Cobas; Roche
Diagnostics), with an interassay CV of <6.5% and a LOQ of
10 ng/L.
Sclerostin
The osteocyte‐derived glycoprotein sclerostin(38) was measured
using an immunoassay (LiasonXL; Diasorin, Saluggia, Italy), with
an interassay CV of 7.5% and a LOQ of 2.2 pmol/L.
Other measurements
25OHD
Liquid chromatography–tandem mass spectrometry (LC‐MS/MS)
was used to measure 25OHD with a CV of 8% and a LOQ of 4.0
nmol/L until 2015.(39) From then on, another LC‐MS/MS method
was used.(40) Both methods resulted in comparable concentra-
tions.
Testosterone
A radioimmunofrequent assay (RIA; Coat‐A‐Count; Siemens Medical
Solutions USA, Malvern, PA, USA; an interassay CV of 7% to 20%, a
LOQ of 1 nmol/L) was used to measure testosterone until January
2013. From then on, a competitive immunoassay was used
(Architect; Abbott Laboratories, Abbott Park, IL, USA; an interassay
CV of 6% to 10%, a LOQ of 0.1 nmol/L). The RIA‐based
concentrations were converted to concentrations of the
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competitive immunoassay using the formulas: Architect=
1.1 * RIA+ 0.20 (for testosterone concentrations<8 nmol/L) and
Architect= 1.34 * RIA – 1.65 (for testosterone concentrations
>8 nmol/L) to evaluate and report comparable testosterone
concentrations.
Estradiol
A competitive immunoassay (Delfia; PerkinElmer, Turku, Finland;
interassay CV of 10% to 13%, LOQ of 20 pmol/L) was used to
measure estradiol until July 2014. Subsequently, an LC‐MS/MS
(Amsterdam University Medical Center; an interassay CV of<7%,
a LOQ of 20 pmol/L) was used. The Delfia concentrations were
converted to the LC‐MS/MS concentrations by using the formula
LC‐MS/MS= 1.60 * Delfia – 29.
Creatinine, aspartate transaminase (AST), alanine transami-
nase (ALT), and gamma‐glutamyltransferase (γGT) concentra-
tions were all measured using an immunoassay (Cobas; Roche
Diagnostics).
DXA
DXA (Hologic Discovery A; Hologic Inc., Bedford, MA, USA) was
used to measure BMD in g/cm2 of the total hip (TH) and
femoral neck (FN) of the nondominant hip and the lumbar
spine (LS), measuring the first four lumbar vertebrae (L1 to L4).
The software was updated from version 13.3 to 13.5.3 in July
2015, which did not affect the results of the measurements.
Baseline DXA was performed 3 months before to 1 month after
the start of HT. The follow‐up DXA was performed between 10
and 14 months after the start of HT.
Statistics
For statistical analyses, Stata/SE 15 (StataCorp, LP, College Station,
TX, USA) was used. The median with corresponding interquartile
range (IQR), percentages, or means with SD were used to describe
baseline characteristics. The percentage change was calculated for
all BTMs and BMDs to evaluate differences between baseline and
1‐year HT. As these changes were normally distributed, linear
regression analyses were performed to evaluate mean changes in
percentage with corresponding 95% CI. Next, these percentage
difference variables were adjusted for changes in BMI, alcohol and
tobacco use, 25OHD, creatinine, AST, ALT, and γGT concentrations.
Participants were stratified for both age and sex steroid
concentrations, with the following age groups: 18 to 30 years,
30 to 50 years, and ≥50 years. By using these separate age groups,
age‐related differences in BMD caused by decreasing bone mass
with increasing age after reaching peak bone mass is accounted
for; it is expected that bone mass decreases throughout time as
described.(5) Linear regression was performed to evaluate possible
differences between the separate age groups. Furthermore,
participants were stratified into quartiles based on their mean
estradiol and testosterone concentrations during HT, which were
calculated by an average of the concentrations after 3 and
12 months of HT. This stratification was applied to detect possible
differences between the effects of either low or high sex steroid
concentrations. Furthermore, a power analysis was performed.
The analysis was applied to the study population of 121
transwomen and 132 transmen to detect the mean differences
of both BMD and separate BTMs with a power of 80% and alpha
of 0.05. This resulted in the detection of a mean difference of LS
BMD of 0.021 g/cm2 in transwomen and 0.022 g/cm 2 in transmen.
Regarding BTMs, in transwomen a 10% change in CTx, 9% change
in P1NP, 4% change in ALP, and 6% change in sclerostin could be
detected. In transmen, a change of 10%, 13%, 6%, and 7% could
be detected, respectively. Pearson correlations were calculated
between the change in BTMs and BMD and are displayed with
corresponding 95% CI (Table 3).
Results
General
A total of 253 people were included in this study (Fig. 1), which
consisted of 121 transwomen with a median age of 30 (IQR 24
to 41) years and 132 transmen with a median age of 24 (IQR 21
to 33) years. The baseline and follow‐up characteristics are
displayed in Table 1. In transwomen, a median increase in
estradiol of 129 pmol/L (IQR 56 to 232) implying a percentage
change of estradiol of 128% (IQR 52 to 214) and a median
decrease in testosterone of –18 nmol/L (IQR –22 to –14) with a
percentage decrease of –96% (IQR –97 to –94) was seen during
the first year of HT. In transmen, a median increase in estradiol
of 46 pmol/L (IQR –304 to 135) with a percentage change of
26% (IQR –63 to 198), which was accompanied by a median
increase in testosterone of 27 nmol/L (IQR 20 to 38) and a
percentage increase of 2248% (IQR 1311 to 3338) was seen
during the first year of HT.
In both groups, the BMI increased and tobacco use
decreased during 1 year of HT (Table 1).
Transwomen
ALP, CTx, and sclerostin decreased by 19% (95% CI, –21 to –16),
11% (95% CI, –18 to –4), and 8% (95% CI, –13 to –4), respec-
tively, in the unadjusted model after 1 year of HT (Table 2).
Adjusting the percentage changes in all BTMs for changes in
BMI, smoking habits, alcohol use, 25OHD, creatinine, AST, ALT,
and γGT concentrations did not affect the results (Table 2). No
difference between the different age groups in change in BTMs
was found (Fig. 2). Sclerostin decreased in all, but the lowest
estradiol quartile (Fig. 3).
Transmen
P1NP, ALP, and sclerostin increased by 33% (95% CI, 24 to 42),
16% (95% CI, 12 to 20), and 15% (95% CI, 10 to 20), respectively,
after 1 year of HT (Table 2). Adjusting these percentage changes
in BTMs for changes in BMI, smoking, alcohol use, creatinine,
25OHD, AST, ALT, and γGT did not affect the results (Table 2).
More detailed analyses based on the earlier specified age groups
revealed an opposite effect on bone turnover in the transmen
aged≥50 years after 1 year of HT compared with younger
transmen (Fig. 2). In transmen aged≥50 years, a decrease in
P1NP of –19% (95% CI, –35 to ‐4), CTx of –32% (95% CI, –50
to –13), and sclerostin of –10% (95% CI, –19 to 0) was found.
Estradiol concentrations increased more in the transmen
aged≥50 years (median increase of 135 pmol/L, IQR 100 to
164) compared with transmen<50 years (median increase of 30
pmol/L, IQR –336 to 124). Different absolute concentrations of
testosterone and estradiol concentrations during HT did not
result in different effects in the course of BTMs during 1 year of
HT (Fig. 3).
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Correlations between BTMs and BMD
Correlations between percentage change in BTMs and percentage
change in BMD for transwomen and transmen are displayed in
Table 3. The changes in BMD after 1 year of HT in this transgender
population was described extensively in earlier research.(5) In
transwomen, an increase in sclerostin was associated with a
decrease in TH BMD. No correlations between change in BTMs and
FN BMD were seen. Furthermore, P1NP, ALP, and CTx showed a
modest negative correlation with LS BMD after 1 year of HT. In
transmen, only P1NP showed a modest negative correlation with
TH and FN BMD. CTx showed amodest negative correlation with LS
BMD in transmen (Table 3). Subgroup analyses were performed
based on the baseline LS BMD data, which we divided into tertiles.
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Fig. 1. Flowchart of inclusion and exclusion of participants. ENIGI= European Network for Investigation of Gender Incongruence.
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This resulted in a mean (±SD) BMD of group 1 (0.817± 0.065),
group 2 (0.972± 0.036), and group 3 (1.120± 0.082) in trans-
women. In transmen, this resulted in a mean BMD (±SD) of
group 1 (0.893± 0.050), group 2 (1.017± 0.029), and group 3
(1.167± 0.075). Based on these tertiles, we evaluated changes of
BTMs per tertile. This resulted in a decrease of P1NP, CTx, ALP, and
sclerostin in transwomen, which was similar for all tertiles. In
transmen, an increase of all markers except CTx was found, which
was similar for the tertiles. In CTx, an increase was found in all, but
the highest BMD group (group 3).
Discussion
This study evaluates changes in a variety of BTMs, sclerostin,
and their correlation with changes in BMD in transgender
people during the first year of HT. In transwomen, a decrease in
bone turnover was seen during the first year of HT, irrespective
of age. In transmen, bone turnover increased in the younger
groups, and decreased in the oldest transmen. No differences
were seen between the different estrogen concentrations and
percentage change in BTMs. Lastly, BTMs showed some modest
negative correlations with changes in the LS BMD of trans-
women predominantly.
Effects on bone turnover after one year of HT
Transwomen
This is the first study to evaluate sclerostin concentrations in
transgender people. It is known that sclerostin concentrations are
higher in men than women and sclerostin increases gradually
with age in both sexes.(41) We found that sclerostin decreased in
transwomen after 1 year of HT. Previous research suggested that
estrogen results in a decrease in sclerostin, which is thought to
result in an increase in BMD, as sclerostin is an important inhibitor
of the anabolic Wnt/β‐catenin signaling pathway in osteo-
blasts.(28,29) An earlier study in premenopausal estrogen‐sufficient
women did not show changes in serum concentrations of
sclerostin during their menstrual cycle and also did not show a
relationship with estradiol concentrations.(42) Withdrawal of
estrogens, however, resulted in an increase in sclerostin in both
postmenopausal women and elderly men, suggesting an inverse
association between sclerostin and estrogen concentrations.(43) A
longitudinal study in Japanese women also showed a decrease in
estrogen and increase in sclerostin concentrations during
menopause, which resulted in increased bone resorption.(7) The
current study showed a decrease in sclerostin in transwomen after
1 year of HT. This finding provides additional evidence that
estrogen treatment results in a decrease in sclerostin concentra-
tions, which has beneficial effects on bone turnover. This finding
aligns well with another study showing that treatment of
postmenopausal women with the SERM raloxifene suppresses
sclerostin.(44)
The finding that CTx decreased during HT is also in line with
the hypothesis that the increase in estrogen concentrations
reduces osteoclast activity and thereby inhibits bone resorp-
tion. Although one study found no change in CTx caused by HT
in transwomen,(22) two other studies also found a decrease in
CTx concentrations within 2 years of HT and lower CTx
concentrations compared with control men after 8 years of
HT.(23,45) Furthermore, ALP decreased during HT. A decrease in
ALP was earlier found within the first year of HT(15) and during
longer follow‐up.(12) Earlier studies also showed a decrease in
P1NP within 2 years of HT,(45) and lower P1NP concentrations
after 8 years of HT compared with control men,(23) whereas one
study showed no changes in P1NP after 3 years of HT.(22) In
addition, the lowest estradiol quartile showed opposite or even
no changes in BTMs compared with the other three estradiol
quartiles in transwomen, which implies that the estrogen
concentrations in the lowest quartile might be too low to result
in a decrease in bone turnover. Overall, the decrease in BTMs in
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Table 1. Participant Characteristics at Baseline and After 1 Year of HT
Transwomen (n= 121) Transmen (n= 132)
Baseline 1 year of HT Baseline 1 year of HT
General
Age, year (median, IQR) 30 (24 to 41) 24 (21 to 33)
Ethnicity (% white) 96.7 91.7
BMI, kg/m2 (median, IQR) 22.9 (20.8 to 26.1) 24.1 (21.9 to 26.3) 24.5 (21.4 to 29.0) 25.4 (22.5 to 29.2)
Tobacco use (% yes) 24.0 14.0 29.2 20.0
Cigarettes/day (median, IQR) 10 (5 to 10) 6 (4 to 20) 8 (4 to 15) 7 (3 to 15)
Alcohol use (% yes) 46.3 45.6 51.2 47.5
Units/week (median, IQR) 2 (1 to 5) 2 (2 to 4) 2 (1 to 4) 3 (2 to 5)
Biochemical results (median, IQR)
Estradiol, pmol/L 105 (84 to 133) 204 (137 to 328) 187 (67 to 525) 181 (132 to 261)
Testosterone, nmol/L 19.0 (14.0 to 23.0) 0.7 (0.5 to 1.0) 1.3 (1.0 to 1.7) 29 (20 to 39)
LH, U/L 3.2 (2.3 to 4.3) 0.1 (0.1 to 0.1) 5.0 (2.7 to 6.9) 1.5 (0.2 to 3.6)
25OHD, nmol/L 39 (25 to 57) 60 (40 to 76) 54 (30 to 77) 57 (41 to 80)
Creatinine, µmol/L (mean± SD) 77± 10 73± 10 66± 10 79± 12
AST, U/L 24 (20 to 28) 20 (17 to 23) 21 (19 to 25) 24 (20 to 28)
ALT, U/L 22 (16 to 30) 21 (15 to 27) 17 (13 to 24) 22 (17 to 29)
γGT, U/L 20 (15 to 28) 19 (15 to 26) 15 (12 to 23) 17 (12 to 26)
HT= gender‐affirming hormonal treatment; IQR= interquartile range; LH= luteinizing hormone; AST= aspartate transaminase; ALT= alanine
transaminase; γGT= gamma‐glutamyltransferase.
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transwomen further supports the bone‐preserving role of
estrogens.
Transmen
Sclerostin increased in the younger transmen after 1 year of HT.
The effect of androgens on sclerostin concentrations are not fully
elucidated yet. An earlier study found a possible direct androgen
receptor‐mediated effect on the production of sclerostin and
negative correlation between sclerostin concentration and
testosterone concentrations in birth‐assigned men.(46) However,
the current study did not show a decrease in sclerostin in
transmen who had higher testosterone concentrations after
1 year of HT. On the other hand, another study showed that
predominantly estrogen and not testosterone mediated the
decrease of sclerostin.(43) However, as both testosterone and
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Table 2. Baseline and 1‐Year Concentrations of Bone Turnover Markers and BMD With Corresponding Percentage Change (Mean
and 95% CI), for Transwomen and Transmen Separately





P1NP, µg/L (median, IQR) 50 (42 to 65) 48 (38 to 62) –3 (–9 to 3) –8 (–17 to 1)
18 to 30 years 61 (49 to 74) 52 (47 to 75) –2 (–10 to 6) n.a.
30 to 50 years 48 (38 to 52) 46 (35 to 54) +2 (–10 to 14) n.a.
≥50 years 40 (33 to 43) 29 (22 to 39) –15 (–29 to –1) n.a.
ALP, U/L (mean± SD) 70± 17 57± 17 –19 (–21 to–16) –21 (–25 to 18)
18 to 30 years 72± 19 60± 18 –17 (–21 to –13) n.a.
30 to 50 years 69± 16 53± 13 –23 (–27 to –19) n.a.
≥50 years 67± 13 58± 19 –14 (–24 to–4) n.a.
CTx, ng/L (median, IQR) 428 (306 to 538) 329 (265 to 442) –11 (–18 to–4) –11 (–23 to 1)
18 to 30 years 507 (387 to 658) 351 (309 to 476) –17 (–26 to –9) n.a.
30 to 50 years 371 (275 to 500) 313 (265 to 452) –1 (–17 to 14) n.a.
≥50 years 287 (198 to 369) 224 (165 to 279) –12 (–32 to 7) n.a.
Sclerostin, pmol/L (median, IQR) 10.4 (8.6 to 14.9) 8.8 (7.3 to 13.5) –8 (–13 to –4) –9 (–16 to –2)
18 to 30 years 8.8 (7.7 to 11.0) 7.7 (6.6 to 9.4) –8 (–15 to 0) n.a.
30 to 50 years 11.4 (9.4 to 15.0) 11.0 (8.1 to 13.4) –9 (–15 to –2) n.a.
≥50 years 17.7 (16.0 to 21.9) 17.9 (14.1 to 18.5) –10 (–22 to 2) n.a.
DXA
BMD TH g/cm2 (mean± SD) 0.938± 0.137 0.947± 0.137 +1.0 (0.5 to 1.5) +0.8 (0.1 to 1.6)
BMD FN g/cm2 (mean± SD) 0.797± 0.127 0.812± 0.129 +1.9 (1.3 to 2.5) +1.6 (0.7 to 2.5)
BMD LS g/cm2 (mean± SD) 0.968± 0.139 1.004± 0.138 +3.8 (3.1 to 4.6) +3.2 (2.0 to 4.4)
Transmen
Bone turnover markers
P1NP, µg/L (median, IQR) 56 (43 to 71) 71 (49 to 100) +33 (24 to 42) +29 (11 to 48)
18 to 30 years 60 (50 to 77) 85 (67 to 111) +42 (30 to 54) n.a.
30 to 50 years 40 (36 to 52) 53 (37 to 60) +21 (10 to 33) n.a.
≥50 years 46 (41 to 66) 41 (29 to 55) –19 (–35 to –4) n.a.
ALP, U/L (mean± SD) 67± 19 76± 22 +16 (12 to 20) +15 (7 to 23)
18 to 30 years 68± 20 80± 23 +19 (14 to 24) n.a.
30 to 50 years 62± 18 68± 17 +14 (5 to 24) n.a.
≥50 years 72± 21 65± 23 –12 (–24 to 1) n.a.
CTx, ng/L (median, IQR) 423 (323 to 533) 432 (313 to 529) +3 (–4 to 10) –5 (–19 to 8)
18 to 30 years 448 (384 to 590) 442 (364 to 586) +3 (–4 to 11) n.a.
30 to 50 years 297 (222 to 386) 313 (215 to 387) +12 (–6 to 30) n.a.
≥50 years 427 (305 to 547) 222 (193 to 381) –32 (–50 to–13) n.a.
Sclerostin, pmol/L (median, IQR) 8.7 (6.8 to 13.1) 10.3 (7.9 to 13.2) +15 (10 to 20) +10 (–0 to 20)
18 to 30 years 7.6 (6.5 to 9.5) 8.8 (7.4 to 11.3) +20 (13 to 26) n.a.
30 to 50 years 13.9 (8.8 to 16.8) 14.3 (10.8 to 18.1) +10 (1 to 19) n.a.
≥50 years 15.9 (14.8 to 17.8) 15.3 (13.2 to 16.3) –10 (–19 to 0) n.a.
DXA
BMD TH g/cm2 (mean± SD) 0.948± 0.113 0.956± 0.114 +0.9 (0.4 to 1.4) +0.0 (–0.9 to 0.9)
BMD FN g/cm2 (mean± SD) 0.833± 0.116 0.825± 0.116 –0.9 (–1.6 to –0.1) –2.5 (–3.7 to–1.2)
BMD LS g/cm2 (mean± SD) 1.026± 0.125 1.036± 0.129 +1.0 (0.4 to 1.7) +2.1 (0.9 to 3.4)
HT= gender‐affirming hormonal treatment; IQR= interquartile range; ALP= alkaline phosphatase; TH= total hip; FN= femoral neck; LS= lumbar
spine; n.a.= not applicable.
aAdjusted for changes in BMI, alcohol and tobacco use, 25OHD, creatinine, AST, ALT, and γGT. Data only shown for the total adjusted group, as
separate adjusted age groups resulted in too small groups for multivariable analyses.
Journal of Bone and Mineral Research BONE TURNOVER DURING HORMONE TREATMENT IN TRANSGENDER PEOPLE 1867 ■
estradiol concentrations changed in transmen, we were not able
to determine the isolated effect of testosterone. Also, this result
can be explained by the use of different sclerostin assays in
previous literature with sometimes high variability between
various sclerostin assays.(47)
With regard to bone formation, an increase in P1NP and ALP was
seen after 1 year of HT. An earlier prospective study also showed an
increase in P1NP with respect to no changes in control women.(24)
Furthermore, P1NP concentrations in transmen aged 37± 8 years
were approximately 25% higher compared with control women
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Fig. 2. Percentage change in bone turnover markers in transwomen and transmen after 1 year of hormone therapy, stratified by age groups. Group
1= 18 to 30 years [transwomen mean age 24 (2.9 SD), n= 61, transmen mean age 23 (3.0 SD), n= 91]. Group 2= 30 to 50 years [transwomen mean
age 39 (5.2 SD), n= 42, transmen mean age 39 (5.9 SD), n= 32]. Group 3= group≥50 years [transwomen mean age 56 (5.8 SD), n= 18, transmen
mean age 54 (4.1 SD), n= 9]. ALP= alkaline phosphatase. *p ≤ 0.05.
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after 10 years of HT,(24) which is comparable to the 21% change
reported in our study in this age group. Regarding ALP, earlier
studies showed an increase of approximately 13% in ALP within the
first year of HT in transmen aged 16 to 40 years,(15) which is also in
line with the 13% change reported in our study. A previous study in
postmenopausal women showed that ALP concentrations were
higher compared with premenopausal women, and that ALP was
negatively correlated with the estradiol concentration of the
postmenopausal group.(48) The bone‐specific alkaline phosphatase
fraction instead of total ALP is a more sensitive parameter to
evaluate bone formation, as increased serum ALP can also result
from liver or gallbladder disease.(38) However, the transmen did not
show signs of liver disease because all liver parameters besides ALP
did not change during 1 year of HT, so it is not expected that this
affected our results. As muscle mass increased in transmen, which is
confirmed by an increase in creatinine after 1 year of HT,
mechanical loading on bones increased, which possibly explains
the increase in bone formation markers.(31) Concerning bone
resorption, the current study showed no increase in CTx in
transmen after 1 year of HT. Earlier studies in transmen showed an
increase in CTx after 1‐year HT compared with no changes in
control women.(20) Also, transmen had higher CTx concentrations
compared with control women after 10 years of HT.(24) CTx was
measured in a fasting state, just as in the studies mentioned earlier.
As CTx is cleared by the kidney,(38) higher concentrations of CTx can
be found in case of impaired kidney function, yet our study
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Fig. 3. Percentage change in bone turnover markers by quartiles of average estradiol and testosterone concentrations measured at 3 and 12 months
after baseline. Testosterone concentrations in transwomen were<2 nmol/L; therefore, this group was not further divided into subgroups.
ALP= alkaline phosphatase. *p ≤ 0.05.
Table 3. Correlation Between Percentage Change in Bone
Turnover Markers and Percentage Change in BMD (mean and
95% CI), Separately for Transwomen and Transmen
Transwomen TH BMD % FN BMD % LS BMD %
























Transmen TH BMD % FN BMD % LS BMD %

























Bold text indicate p ≤ 0.05.
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population had no impaired kidney function. Alternatively, the
fasting state was based on self‐report of the participants during
follow‐up. Therefore, it is possible that some participants did not
apply the instructions to draw blood in a fasting state. This might
have masked the increase of CTx because CTx decreases in relation
to food ingestion.(38) Lastly, when comparing age groups, the
oldest transmen group showed a decrease in all BTMs and
sclerostin in contrast with the younger transmen. The older group
of transmen benefited the most from HT as they were assumed to
be estrogen‐deficient as a result of their postmenopausal state at
baseline (mean age 54 years, SD 4.1). In most studies in transmen,
estradiol concentrations either remain stable or decrease slightly.
However, two studies investigating the effect of testosterone in
combination with an aromatase inhibitor found that estradiol
concentrations remained stable in transmen using testosterone
only, but decreased to a great extent in transmen using both
testosterone and an aromatase inhibitor.(49,50) This indicates that
the estradiol concentrations mainly result from the aromatization of
testosterone into estradiol. This is also supported by our finding
that estradiol concentrations increased in transmen who were
postmenopausal and therefore estrogen‐deficient before the start
of HT. The increase in estrogen concentration after the aromatiza-
tion of testosterone resulted in decreased bone resorption, which
further strengthens the beneficial role of estrogen on bone health.
Associations between BTMs and BMD
Modest negative correlations were found between changes in
BTMs and changes in BMD during 1 year of HT. This finding is in
line with previous research in transwomen, where no correla-
tions between CTx and P1NP and volumetric BMD (vBMD) of
the radius or tibia where found.(22) In transmen, only an inverse
relationship with CTx and P1NP and vBMD at the radius and
tibia was found.(24) Changes in BTMs were predominantly
correlated to the LS BMD of transwomen. LS consists mainly of
trabecular bone, which is more metabolically active compared
with the hip, which mainly consists of cortical bone.(51,52) This
was not seen in the FN, although this region also contains
significant trabecular bone albeit less compared with LS. This
finding further emphasizes the role of estradiol in maintaining
adequate bone homeostasis, which is already well‐studied in
men.(53,54) Also, earlier research about estrogen supplementa-
tion therapy in postmenopausal women showed an increase in
BMD and a decrease in BMD after the discontinuation of
estrogen supplementation in a large female cohort.(55) Next to
this, a murine model studying ovariectomized mice showed
that estrogen therapy had more beneficial effects on bone
architecture compared with mice treatment with testosterone
alone.(56) Summarized, the increase in BMD after 1 year of HT in
both transwomen and transmen found in this study further
emphasizes the beneficial effect of estrogen on bone.
Strengths and limitations
Data for this study were collected during patient care following a
standardized treatment protocol. As a result, this prospective
study consisted of a large study population compared with other
studies in transgender people, thereby ensuring a study
population with a broad variation in age. Other strengths of
this study were(1): the use of the same BTM assays(2); all samples
were thawed simultaneously; and (3) all analyses were performed
using one lot number. Moreover, this study is the first to
evaluate BTM sclerostin in transgender people. In addition, the
same DXA scanner was used both at baseline and during
follow‐up.
This study also has some limitations. First, no control group
was included; therefore, changes in time as a cause for changes
in BTMs or BMD could not be evaluated. However, as the study
population consisted of different age groups, almost all
participants already had reached their peak bone mass; this
would have resulted in decreasing BMD through time and
increased bone turnover, especially in postmenopausal women.
From earlier studies, it is known that bone turnover increases
with age, after the initial high levels that are reached during
puberty.(57–59) As part of standard patient care, participants were
advised on the principles of a healthy lifestyle and physical
activity, as well as maintaining adequate calcium and 25OHD
intake. This resulted in changes in 25OHD concentrations during
1‐year HT, but adjustments for these changes did not affect our
results. No full data on earlier dietary calcium intake, steroid use,
fractures, weight‐bearing exercise, or family history were
available. Furthermore, a 3‐month measurement of BTMs was
not available. Because of the observational character of this
study, this study was not designed to evaluate possible causal
relationships. Nevertheless, this study further contributes to the
current hypothesis that sclerostin is a mediating factor in the
anabolic effect of estradiol on bone turnover and BMD. Lastly,
follow‐up data regarding fractures were lacking.
To conclude, this study provides additional knowledge
regarding the effect of HT on bone metabolism and BMD in
transgender people and emphasizes the importance and
beneficial effect of estrogen by decreasing bone turnover and
increasing BMD. Summarized, this study shows that 1 year of
HT does not result in deleterious effects on bone health in
transgender people. Despite these results, the effects after
multiple years of HT, particularly for younger transmen, are of
great interest for future study. Given the still increasing
incidence and the need for the treatment of transgender
people, additional studies should be performed to evaluate the
longer term relationships between change in bone turnover,
BMD, and fracture risk during HT in transgender people.
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